CSI Market
Sign In | Register

Lineage Cell Therapeutics Inc (LCTX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access LCTX Annual Cash Flow →
From Lineage Cell Therapeutics Inc through Jun 30 2025, changes in Jun 30 2026's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-21.67
Depreciation & amortization0.38
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue-1.69
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total-0.03
Share-based Compensation2.77
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-11.05
Amortization Of Deferred Consulting Fees-
Amortization Of Deferred License Fees And Royalty Fees-
Amortization Of Deferred Rent-
Amortization Of Deferred Charges-
Amortization Of Stock Based Prepaid Rent-
Write Off Of Security Deposit-
Reclassification Of Licensing Fees-
Officers Compensation-
Warrants Issued For Interest Expense-
Modification Cost Of Warrants-
Share In Net Loss From Associate-
Research And Development N Process Purchased-
Write Off For Uncollectible Receivables-
Accrued Interest On Convertible Debt-
Deconsolidation Gain Or Loss Amount-
Proceeds From Deferred Grant Income-
Accretion Of Income On Marketable Debt Securities-0.16
Marketable Securities Unrealized Gain Loss-
Gain On Revaluation Of Warrant Liability Related To Operating Activites-
Change In Rightofuse Assets And Liabilities-0.01
Foreign Currency Remeasurement Gain Loss Before Tax-0.02
Income taxes0.00
Gain on Sale of Investments0.00
Increase (Decrease) in Accounts Receivable-0.17
Increase (Decrease) in Accounts Payable and Accrued Liabilities-2.05
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.09
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.09
Payments for (Proceeds from) Other Operating Activities19.21
Discontinued operations0.00
Net Cash flow from Operating Activities-15.32
Investing Activities
Capital Expenditures-0.16
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities20.46
Payments to Acquire Marketable Securities-18.66
Real Estate Investments0.00
Security Deposit Received-
Note And Related Interest Accrued For Acquisition-
Payment Of License Fee-
Cash Acquired In Connection With Merger-
Payment Of Transaction Fees-
Payment Of Syndication Fees Incurred-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities1.63
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock5.62
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-0.04
Other net4.45
Proceeds From Employee Options Exercised-
Proceeds From Director Options Excercised-
Fees Paid On Sale Of Common Shares-
Proceeds From Exercise Of Stock Options From Employees-
Proceeds From Exercise Of Stock Options From Director-
Proceeds From Exercise Of Stock Options From Outside Consultant-
Financing Fees Paid Upon Issuance Of Common Shares-
Capital Leases Income Statement Amortization Expense-
Fees Paid On Sale Of Common Shares Of Subsidiary-
Proceeds From Construction In Progress-
Proceeds From Stock Options Exercised Of Subsidiary-
Proceeds From Warrants Exercised Of Subsidiary-
Proceeds From Sale Of Treasury Shares And Issuance Of Subsidiary Warrants-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities10.03
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-15.49
Total Cash Flow-3.41
4 historic quarters locked

Sign in to unlock the full Lineage Cell Therapeutics Inc cash flow history.

Sign In Create Free Account

About Lineage Cell Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-338064

Figures are derived from filed reports and may be restated. Historical data is subject to revision.